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INTRODUCTION 
 
 
          Available evidence in literature has shown that Coronary Heart 
Disease (CHD) is progressively increasing in Indian population and 
projected to be the number one killer in the next decade (1). Traditional risk 
factors like smoking, hyper-tension, diabetes are reported to account for only 
50% of prevalence and severity of the disease (2). This led to studies on 
newer risk factors like fibrinogen, Lipoprotein Lp(a), homocysteine, tissue 
plasminogen activator etc. 
                               The role of lipoprotein(a) [Lp(a)] as a risk factor for 
ischemic heart disease (IHD) has received considerable attention in recent 
years.    Studies on overseas Indians have shown that Lp(a) is an important 
risk factor for  Coronary Artery Disease. Lp(a) resembles the LDL particle in 
structure. Apolipoprotein B is the major apolipoprotein associated with LDL; 
in Lp(a), however, an additional apolipoprotein, apolipoprotein(a), is bound 
covalently to apolipoprotein B . The physiology and function of Lp(a) are 
still poorly understood, but the apolipoprotein(a) molecule demonstrates high 
sequence homology  with plasminogen. This suggests that Lp(a) might 
contribute to the thrombotic, as well as to the atherogenic, aspects of IHD .  
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                                     Studies on evidence of relationship between Lp(a) 
and CHD have shown higher levels of Lp(a) in patients than in controls (3-
5). Significant relationship of Lp(a) with CHD is reported in South Indian 
studies (6,7). 
The prevalence of dyslipidemia varies by population. Its incidence is 
highest in patients with premature CHD. (CHD before 55  years of age in 
men and 65 years in women). Lipoprotein Lp(a) excess has been identified 
as a powerful predictor of premature atherosclerotic vascular disease in 
several large, prospective studies. Lipoprotein Lp(a) levels modulate the risk 
of coronary heart disease in patients with hypercholesterolemia, and 
lipoprotein Lp(a) excess is commonly detected in men and women with 
premature coronary atherosclerosis. Lp(a) excess increases the risk of 
premature CHD 3 to 100 fold depending on the absence or presence of 
concomitant risk factors (8). 
 
                                  Lp(a) levels correlate with both early and advanced 
atherosclerosis, severity, extent and progression of atherosclerosis and all 
complications of CHD including re-stenosis following percutaneous 
transluminal angioplasty, stent and bypass surgery (5).  
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                         Study of Lp(a) will help in the process of identifying the risk 
factors associated with the malignant nature of CHD in Indian population. 
Also measurement of Lp(a) levels in different populations can help in 
identifying the high risk group requiring aggressive pharmacological 
treatment (9, 10). In consideration of the high prevalence of lipoprotein 
Lp(a) excess in patients with premature coronary heart disease and the 
intricate role of lipoprotein Lp(a) in atherothrombosis, the present study was 
undertaken to find out the association of Lp(a) with Premature CHD in a 
south Indian population from coimbatore. 
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AIM OF THE STUDY 
 
 
1.  To find out the association of High Lipoprotein (a) levels with 
premature  coronary artery disease patients 
                   
2. To find the association of high Lipoprotein (a) levels with          
the   following Risk  factors in patients with premature  coronary artery 
disease 
 
1.Systemic hypertension 
2.Type 2-Diabetes mellitus 
3.Hypercholesterolemia 
4.High Low Density Lipoprotein (LDL) 
5.Low High Density Lipoprotein (HDL) 
6.Hyper-triglyceridemia 
7.Smoking 
8.Positive family history  
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REVIEW OF LITERATURE 
A. ANATOMY OF CORONARY CIRCULATION 
                   The coronary arteries take origin from the right and 
left coronary sinuses. In 85% of patient the right coronary artery which 
gives rise to posterior descending artery supplies the entire right ventricle 
and large a part of the posterior wall of the left ventricle. This is referred 
to as right dominant circulation.  In 8% of patients the left coronary artery 
supplies entire left ventricle, interventricular septum and portion of right 
ventricle. This is referred to as left dominant circulation.  In 7% of 
patients referred to as co-dominant circulation, the right coronary artery 
supplies right ventricle and posterior wall of interventricular  septum 
while left coronary supplies the left ventricle and anterior portion of 
interventricular septum.  
 
FIG-1: Anatomy of heart and circulation 
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PATHOPHYSIOLOGY OF CORONARY CIRCULATION 
 
                           The normal coronary circulation is dominated and 
controlled by the heart's requirements for oxygen. The large epicardial 
coronary arteries are capable of constriction and relaxation and are referred 
to as conductance vessels, while the intramyocardial arterioles normally 
exhibit changes in tone and are therefore referred to as resistance vessels 
.Changing oxygen needs of the heart with exercise and emotional stress 
affect coronary vascular resistance and in this manner regulate the supply of 
oxygen and substrate to the myocardium (metabolic regulation). The 
coronary resistance vessels also adapt to physiologic alterations in blood 
pressure in order to maintain coronary blood flow at levels appropriate to 
myocardial needs (auto regulation).  
                                    By reducing the lumen of the coronary arteries, 
atherosclerosis limits appropriate increases in perfusion when the demand 
for flow is augmented, as occurs during exertion or excitement. When the 
luminal reduction is severe, myocardial perfusion in the basal state is 
reduced. Coronary blood flow can also be limited by spasm, arterial thrombi, 
and, rarely, coronary emboli as well as by ostial narrowing due to luetic 
aortitis. Myocardial ischemia can also occur if myocardial oxygen demands  
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Fig-2: Structure of a normal coronary artery: 
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are markedly increased, and when coronary blood flow may be limited, as 
occurs in severe left ventricular hypertrophy due to aortic stenosis.  
 
CORONARY ATHEROSCLEROSIS : 
 
     Epicardial coronary arteries are the major site of 
atherosclerotic disease. The normal functions of the vascular endothelium 
include local control of vascular tone, maintenance of an anticoagulant 
surface, and defense against inflammatory cells. The loss of these defenses 
leads to inappropriate constriction, luminal clot formation, and abnormal 
interactions with blood monocytes and platelets. The latter results in the 
subintimal collections of fat, smooth-muscle cells, fibroblasts, and 
intercellular matrix (i.e., atherosclerotic plaques), which develop at irregular 
rates in different segments of the epicardial coronary tree and lead eventually 
to segmental reductions in cross-sectional area. When a stenosis reduces the 
cross-sectional area by ~75%, a full range of increases in flow to meet 
increased myocardial demand is not possible. When the luminal area is 
reduced by  80%, blood flow at rest may be reduced, and further minor 
decreases in the stenotic orifice can reduce coronary flow dramatically and 
cause myocardial ischemia.  
       Once stenosis of a proximal epicardial artery has 
reduced the cross-sectional area by 70%, the distal resistance vessels dilate  
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Fig-3:Structure of  the Endothelial barrier  
 
 
 
 
Fig-4:Structure of a normal platelet: 
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to reduce vascular resistance and maintain coronary blood flow. When the 
resistance vessels are maximally dilated, myocardial blood flow becomes 
dependent on the pressure in the coronary artery distal to the obstruction. In 
these circumstances ischemia, manifest clinically by angina or 
electrocardiographically by ST-segment depression, can be precipitated by 
increases in myocardial oxygen demands caused by physical activity, 
emotional stress, and/or tachycardia.  
 
Stages (phases) of progression of atherosclerosis: 
 
PHASE I TO III:  Fatty streak 
PHASE IV :          Diffuse intimal thickening 
PHASEV &VI:     Fibrous Plaque 
 
INITIATION OF ATHEROSCLEROSIS  
FATTY STREAK FORMATION:  
 
                                    "Fatty streak" observed by Stary(11) represents the initial 
lesion of atherosclerosis. The formation of these early lesions arise from 
focal increases in the content of lipoproteins within regions of the intima. 
These lipoproteins bindwith proteoglycan molecules of the arterial 
extracellular matrix, an interaction that may promote the retention of 
lipoprotein particles by binding them and slowing their egress from the  
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Fig-5: Phases of atherosclerosis. 
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intima. Lipoprotein particles in the extracellular space of the intima, 
particularly those bound to matrix macromolecules, may undergo chemical 
modifications that  promote atherogenesis: oxidation and nonenzymatic 
glycation.  
 
Diffuse Intimal Thickening : (Lesion Type IV) 
         Diffuse intimal thickening  consists of increased numbers of 
intimal smooth muscle cells surrounded by variable amounts of connective 
tissue. These lesions do not progress to advanced lesions of atherosclerosis. 
These lesions may also have diffusely extracellular lipid intermixed with 
smooth muscle, macrophages, T cells, and connective tissue. 
 
The Fibrous Plaque (Lesion Types V and VI) 
                        The advanced lesion of atherosclerosis is generally called a 
fibrous plaque. When the fibrous plaque becomes involved with thrombosis, 
hemorrhage, and/or calcification, it is often called a complicated lesion. 
Fibrous plaques are grossly white in appearance and are usually elevated. In 
many cases they protrude into the lumen of the artery and, if sufficiently 
large, compromise the flow of blood. These lesions consist of large numbers 
of intimal smooth muscle cells, together with numerous macrophages and T-
lymphocytes. When the macrophages and smooth muscle contain lipid, the 
lipid is primarily in the form of cholesterol and cholesteryl ester. The  
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                    Fig-6: Surface view of a fatty streak 
                   
 
                            Fig- 7: Structure of a fibrous Plaque 
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proliferated smooth muscle cells are surrounded by collagen and elastic 
fibers, by large amounts of proteoglycan, and, in individuals who are 
hypercholesterolemic, by varying amounts of lipid deposited in the cells and 
in the connective tissue. Fibrous plaques characteristically are covered by a 
fibrous cap. The coronary arteries generally demonstrate the most intense 
involvement, with lesions of atherosclerosis located within the first 6 cm of 
the artery.(12) The rheological forces play a major role in determining the 
localization, extent, and severity of lesions in susceptible individuals.(13,14) 
 
Fig-8: Light microscopic view of a fibrous plaque 
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Table-1:RISK FACTORS FOR CORONARY HEART DISEASE: 
 
 
 
1. AGE: 
 
 Age  is a definite unmodifiable risk factor. Atherosclerosis develops 
progressively as age advances. Atherosclerosis is rarely present in early 
childhood, except in familial hyperlipidemia, but it is often detectable in 
postmortem specimens of young age between 15-30 years. Atherosclerosis 
is universal in elderly. 
 
A. FIXED 
1. Age 
2. Male sex 
3. Family History 
B. MODIFIABLE 
1. Smoking 
2. Hypertension 
3. Lipid Disorders 
4. Diabetes Mellitus 
5.Haemostatic variables 
6. Sedentary Life Style 
7. Obesity 
8. Mental Stress 
9. Personality 
10. Oral Contraceptive Pills 
11. Hyperhomocysteinemia 
12. High LP(a) levels 
13. Inflammation 
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2. SEX: 
  Men are more affected than premenopausal women. However 
after menopause the incidence of atheroma rises in women. This suggests 
that oestrogen probably plays a part in preventing or delaying 
atherosclerosis. There is also a fall in HDL levels in postmenopausal 
women which may also contribute. 
3. FAMILY HISTORY: 
  Coronary artery disease runs in families. This may be due to 
genetic factors or the effects of a shared environment (similar diet, smoking 
habits etc,). A positive family history is generally accepted to refer to those 
in whom a first degree relative of the patient has developed Ischaemic 
Heart Disease before the age of 50 years. 
SMOKING: 
                    The use of tobacco is one of the primary modifiable risk factors 
for CAD. Smoking multiplies the effect of other coronary risk factors and is 
estimated to be the cause of approximately 20 per cent of all deaths of 
cardiovascular disease .In the Framingham Heart Study, cardiovascular 
mortality increased 18 per cent in men and 31 per cent in women for each 10 
cigarettes smoked per day(15) In addition, the use of tobacco products in 
individuals with other cardiac risk factors was found to have a synergistic 
effect on CAD morbidity and mortality. Passive exposure to smoke in 
individuals who have never smoked may also increase risk for CAD 
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                               Smoking may also have a detrimental effect on coronary 
flow. smoking significantly increased the risk for vasospasm; In addition, it 
adversely affects endothelial function,(16) fibrinogen level,(17) and platelet 
aggregation.(18) 
HYPERTENSION : 
                              A wealth of epidemiologic data support a relationship 
between hypertension and atherosclerotic risk, and extensive clinical trial 
evidence has established that pharmacologic treatment of hypertension can 
reduce the risk of stroke and heart failure. More recent studies also show a 
reduction in CHD risk by antihypertensive therapy, particularly interruption 
of the renin-angiotensin system. In a meta-analysis of nine prospective 
studies that together included almost 420,000 individuals without prior 
myocardial infarction or stroke who were followed up for an average of 10 
years, baseline blood pressure level correlated with subsequent incidence 
rates of CAD death and nonfatal myocardial infarction(19). Some studies 
have found a J-shaped relation between blood pressure and CAD events. In 
addition, left ventricular dysfunction may affect blood pressure and increase 
risk for coronary events immediately after a myocardial infarction(20). 
Large-scale prospective interventional trials are under way to clarify this 
issue.(21) 
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DYSLIPIDEMIA: 
                                 The major plasma lipoproteins—chylomicrons, very-
low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), 
low-density lipoprotein (LDL), and high-density lipoprotein (HDL)—are 
distinguished by lipid content, density on ultracentrifugation, size, mobility 
on electrophoresis, and the proteins on their surfaces. The lipoproteins vary 
in their contribution to atherosclerotic risk: The triglyceride-rich 
lipoproteins—chylomicrons and VLDL—are not thought to be atherogenic, 
but the remnants of their lipolysis—chylomicron remnants and IDL, 
respectively—are believed to be atherogenic. The atherogenicity of LDL—
the metabolic end product of VLDL—and lipoprotein(a) [Lp(a)] has been 
established, as has the cardio protective effect of HDL . 
HYPERCHOLESTEROLEMIA: 
                                      The dyslipidemia most clearly associated with 
increased risk for CAD is hypercholesterolemia, particularly elevated plasma 
levels of cholesterol carried in LDL. LDL contains approximately 70 per 
cent of cholesterol in the blood and is the primary target of intervention in 
the guidelines of the second Adult Treatment Panel of the NCEP.(22,23) 
The association between elevated blood cholesterol and CAD has been 
established in observational and interventional epidemiological studies, 
examples of which are presented here. These data support the lipid 
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hypothesis: CAD risk is increased at increasing plasma cholesterol levels and 
can be decreased by decreasing plasma cholesterol. 
OBSERVATIONAL STUDIES: 
                                     A continuous and graded positive relation was 
demonstrated between total cholesterol level and CAD mortality in the more 
than 350,000 men screened for the Multiple Risk Factor Intervention Trial 
(MRFIT)(24). The relation between total cholesterol level and coronary 
disease is not limited by nationality or ethnicity, as demonstrated in the 
Seven Countries Study, which determined that in areas such as Japan and 
countries surrounding the Mediterranean Sea, where the dietary intake of 
saturated fat is low and average plasma cholesterol level is relatively low, 
the mortality rate for CAD is also low, compared with countries such as 
Finland and the United States, where both the average plasma cholesterol 
level and the coronary mortality rate are higher(25) Similarly, in the Ni-Hon-
San Study, men of Japanese descent living in the United States consumed a 
diet higher in fat and cholesterol than Japanese men living in Japan(26) and 
had higher total cholesterol levels(27) and a higher age-adjusted incidence of 
myocardial infarction and CAD death.(28) 
INTERVENTIONAL STUDIES IN PRIMARY PREVENTION:   
                Randomized, controlled clinical trials have employed a variety of 
interventions to determine the efficacy of cholesterol lowering in preventing 
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CAD events in individuals free of known CAD, or primary prevention, and 
in preventing subsequent CAD events in subjects with known CAD, or 
secondary prevention.(29) 
LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION 
TRIAL.(30) 
WORLD HEALTH ORGANIZATION COOPERATIVE TRIAL.   
HELSINKI HEART STUDY(31) 
OSLO STUDY DIET AND ANTISMOKING TRIAL.(32) 
WEST OF SCOTLAND CORONARY PREVENTION STUDY. 
 
INTERVENTIONAL STUDIES IN SECONDARY PREVENTION: 
 
                                Secondary-prevention trials using dietary, 
pharmacological, and/or surgical interventions have demonstrated a decrease 
in the progression of atherosclerotic lesions   and a reduction in CAD 
morbidity and mortality with lipid-regulating therapy.(33) 
CORONARY DRUG PROJECT(34) 
CORONARY INTERVENTION STUDY.(35) 
LIFE STYLE HEART TRIAL(36). 
MONITORED ATHEROSCLEROSIS REGRESSION STUDY. 
CANADIAN CORONARY ATHEROSCLEROSIS INTERVENTION 
TRIAL.(37) 
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Fig-9: Regression of atherosclerotic lesions with therapy: 
 
 
                                         
                                        The Current National Cholesterol Education 
Panel Adult Treatment Panel III (NCEP ATP III)( 38) recommend that 
all individuals aged 20 years or older without CAD or other atherosclerotic 
disease have their total cholesterol and, if accuracy can be assured, HDL 
cholesterol levels measured at least once every 5 years. 
The following  risk factors (besides LDL cholesterol elevation) are included 
in the NCEP’s algorithm: 
Positive risk factors 
• Age (45 years or older in men; 55 years or older, or premature menopause 
without estrogen-replacement therapy, in women) 
• Family history of premature CAD (myocardial infarction or sudden death 
before the age of 55 in father or other male first-degree relative, or before 
the age of 65 in mother or other female first-degree relative) 
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•  Current cigarette smoking/Hypertension ( 140/90 mm Hg, or on 
antihypertensive medication) 
• Low HDL cholesterol (<35 mg/dl) 
• Diabetes mellitus 
Negative risk factor (subtract 1 of the additional risk factors if present) 
• High HDL cholesterol (> 60 mg/dl) 
Obesity is not included in the algorithm, it should be a target for 
intervention, as should physical inactivity. 
In primary prevention, total cholesterol less than 200 mg/dl is considered 
desirable 
The analysis is performed on a sample obtained after a 12-hour fast to allow 
clearance of chylomicrons. Total cholesterol, HDL cholesterol, and total 
triglyceride levels are measured, and LDL cholesterol is calculated by the  
Friedwald formula: 
LDL cholesterol (mg/dl) = Total cholesterol – HDL cholesterol – 
(triglyceride/5) 
The formula is not accurate if triglyceride is greater than 400 mg/dl or if the 
patient has type III hyperlipidemia or is homozygous for apo E2; in these 
instances, LDL cholesterol needs to be determined by ultracentrifugation at a 
specialized laboratory. 
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ELEVATED LIPOPROTEIN(a): 
                           Lp(a) level has been shown in a number of clinical 
studies, primarily retrospective, to be an independent risk factor for 
CAD.(39) Structurally, Lp(a) is identical to LDL with the addition of a 
single apo(a) molecule attached by a disulfide bond to the apo B-100. The 
distribution of Lp(a) concentration is bell shaped in blacks but skewed in 
whites, who typically have levels below 20 mg/dl. A level above 30 mg/dl is 
generally considered elevated. The primary determinant of Lp(a) level has 
been shown to be genetic. In one study in white families, more than 90 per 
cent of the variation in Lp(a) level was attributable to variation in the gene 
for apo(a).(40) Less than 10 per cent of the inherited variation in Lp(a) level 
may be attributable to variations in genes at other loci, such as the B/E 
receptor gene. Lp(a) concentration was reported to be three times higher in 
patients with heterozygous FH than in controls.(41) About 4 per cent of the 
variation in Lp(a) level may be attributable to variation in the gene for apo E: 
Compared with individuals with the gene for apo E3, Lp(a) concentration 
was 25 per cent lower in individuals with the gene for apo E2 and 25 per 
cent higher in individuals with the gene for apo E4.(42) 
              The mechanism by which Lp(a) may increase risk for CAD is 
complex. Lp(a) may interfere with the generation of plasmin because of 
structural similarity between apo(a) and plasminogen.(43) Lp(a) has been 
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demonstrated to be deposited in the arterial wall, particularly in areas with 
atherosclerotic plaque, and apo(a) has been found co-localized with 
fibrinogen in the arterial wall.(44) Lp(a) that has been modified by 
malondialdehyde was  reported to be removed by scavenger receptors on 
macrophages at a rate 20 times higher than that of native Lp(a).(45) Lp(a) 
appears to be more susceptible to oxidative modification than LDL(46) and 
thus may be preferentially taken up by scavenger receptors. Although 
individuals with marked elevations of Lp(a) or homocysteine do appear to 
have heightened risk of coronary thrombosis, in the population at large these 
factors show a much weaker correlation with vascular events than LDL, 
HDL, or the global inflammatory marker C-reactive protein (CRP).  
                                 Treatment of elevated Lp(a) is problematic. Most lipid-
regulating agents do not seem to lower Lp(a), except, as noted above, 
nicotinic acid, bezafibrate, and estrogen. Neomycin(47) and stanozolol48 
have also been reported to decrease Lp(a). Although lowering Lp(a) level is 
theoretically attractive, the clinical impact has not been determined. Because 
Lp(a) measurement is not a widely available laboratory determination and 
the clinical significance of alterations in Lp(a) level is not known, the NCEP 
does not recommend the routine measurement of this lipoprotein at this time.  
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DIABETES MELLITUS, INSULIN RESISTANCE, AND THE 
METABOLIC SYNDROME :  
                                   Diabetes mellitus is a CHD risk equivalent; most patients 
with diabetes mellitus die of atherosclerosis and its complications. The 
abnormal lipoprotein profile associated with insulin resistance, known as 
diabetic dyslipidemia, accounts for part of the elevated cardiovascular risk in 
patients with type 2 diabetes. While diabetic patients often have LDL 
cholesterol levels near average, the LDL particles tend to be smaller and 
denser and thus more atherogenic . Other features of diabetic dyslipidemia 
include low HDL and elevated triglyceride levels 
The antihypertensive regimen for patients with the metabolic syndrome 
should include angiotensin-converting enzyme inhibitors or angiotensin 
receptor blockers when possible. Most of these individuals will require more 
than one antihypertensive agent to achieve the current American Diabetes 
Association blood pressure goal of 130/85 mmHg. (49,50,51) 
Hemostatic Factors 
FIBRINOGEN:    Fibrinogen levels vary among populations. Although 
elevated plasma fibrinogen occurs in conjunction with other CAD risk 
factors, such as age, cigarette smoking, hypertension, and obesity, fibrinogen 
has been demonstrated to be an independent CAD risk factor.52 In 6-year 
follow-up of 2116 men in the PROCAM study, mean plasma fibrinogen 
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level was significantly higher in men who had coronary events (2.88 
gm/liter) than in men who did not have events (2.63 gm/liter), and the 
incidence of coronary events was 2.4 times higher in subjects in the highest 
tertile of plasma fibrinogen distribution (>2.77 gm/liter) than in subjects in 
the lowest tertile (<2.36 gm/liter).(53)  
COAGULATION FACTOR VII:   
         Coagulation factor VII has been shown to increase CAD risk in a 
number of epidemiological studies.(54) factor VII levels are higher in 
individuals with a high intake of dietary fat,(55) and a direct association has 
been established between factor VII and total cholesterol level.(56) Elevated 
factor VII activity may increase thrombin production,(57) further leading to 
a hypercoagulant state. 
FIBRINOLYTIC ACTIVITY: 
          Decreased fibrinolytic activity has been reported in patients with 
coronary atherosclerosis. Studies (58) suggest that the decreased ability to 
lyse a clot and clear fibrin debris may play a role in atherosclerosis. 
PLASMINOGEN ACTIVATOR INHIBITOR :  
                                  Decreased fibrinolytic activity may result from elevated 
levels of PAI-1. In many  studies, plasma PAI-1 has been reported to be 
increased in patients with CAD. PAI-1 was found to be directly related to 
insulin level, confirming the role of PAI-1 in the insulin-resistance 
syndrome.(59) In addition to systemic increases in PAI-1, atherosclerotic 
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lesions have been found to contain higher levels of PAI-1 than the normal 
arterial wall.(60) 
TYPE A PERSONALITY AND STRESS: 
                                 The role of personality type(61) and emotional 
stress(62) in risk stratification for CAD remains controversial. Type A 
personalities are highly competitive, ambitious, and in constant struggle with 
their environment, whereas type B personalities are passive and less 
disturbed by environmental stress. Type A personality was reported to be an 
independent risk factor for CAD in the Western Collaborative Group Study. 
Type A subjects were twice as likely to have angina or myocardial infarction 
as type B subjects.(63) However, in 20 years of follow-up in 1289 men and 
women in the Framingham Heart Study, there was a significant twofold 
excess in risk for angina pectoris in both men and women with type A 
behavior but no association between personality type and risk for either 
myocardial infarction or fatal coronary events.(64)  
FAMILY HISTORY: 
                         Coronary atherosclerosis tends to aggregate in families. In 
studies that controlled for other risk factors, a family history of CAD has 
been shown to be a strong independent risk factor for CAD. Although 
symptomatic CAD typically does not occur until middle age, family history 
of CAD may influence atherosclerotic risk beginning in infancy (66) 
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                       The increased CAD risk associated with a positive family 
history may be mediated by genetic effects on other risk factors such as 
obesity, hypertension, dyslipidemia, and diabetes(67). Assessment of family 
history of these other risk factors may provide additional information about 
an individual’s CAD risk and inform treatment decisions. 
ALCOHOL: 
               The role of alcohol in CAD risk is complicated by difficulties in 
obtaining accurate data on individual alcohol consumption. In a number of 
studies, moderate alcohol intake has been associated with decreased 
coronary risk,(68) and this protective effect may be mediated by an increase 
in HDL cholesterol.(69) In an analysis of subjects in the Honolulu Heart 
Program, approximately 50 per cent of the cardioprotection demonstrated 
with moderate alcohol consumption was attributable to increased HDL 
cholesterol, and 18 per cent was attributable to decreased LDL cholesterol, 
although the latter was offset by an increase in CAD risk of 17 per cent 
caused by increased systolic blood pressure.(70) . Alcohol may inhibit 
thrombosis(71) and may increase plasma levels of fibrinogen and decrease 
fibrinolytic activity.(72) Alcohol has been shown to increase tissue-type 
plasminogen activator (t-PA) secretion by endothelial cells.(73)  
                           In France, CAD incidence is relatively low despite mean 
plasma HDL cholesterol levels similar to those in other countries and fairly 
high intake of saturated fat. Suggested explanations for this so-called French 
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paradox include alcohol-induced inhibition of platelet aggregation(74) and 
antioxidant effects of red wine.(75) 
HOMOCYSTEINE : 
                             A large body of literature suggests a relationship between 
hyperhomocysteinemia and coronary events. Several mutations in the 
enzymes involved in homocysteine accumulation correlate with thrombosis 
and, in some studies, coronary risk. There are no clinical trial data showing 
that intervention to lower homocysteine levels reduces CHD events 
 
ASSOCIATION OF LP (a) WITH CORONARY ARTERY 
DISEASE: 
                         Lp(a) is an LDL like particle which has apolipoprotein(a) 
attached to apolipoprotein B molecule via disulphide bond. There are 34 
different Lp(a) isoforms depending on the size of the apo(a). Lp(a) levels are 
influenced by apo(a) polymorphism. Plasma Lp(a) levels are highly 
heritable. Stable life long levels are attained by age two. The rate of secretion 
by liver determines the Lp(a) levels. Ninety percent of the variation in 
plasma levels is accounted by the apo(a) gene and 70% by the size of apo(a) 
isoforms (76). Mechanism of pathogenecity of Lp(a) excess include 
enhanced thrombogenesis and impaired fibrinolysis by competing with 
plasminogen, inhibition of transforming growth factor β, destabilization of 
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plaque, increased smooth muscle cell proliferation and migration, formation 
of occlusive thrombus, impaired formation of collateral vessels, enhanced 
oxidation uptake and retention of LDL-C and upregulation of expression of 
the plasminogen activator inhibitor (PAI-I) (77-79). 
Lipoprotein(a). A genetic risk factor for premature coronary heart 
disease(80) 
Lipoprotein Lp(a) excess and premature  coronary heart disease(81): 
                             Lipoprotein Lp(a) excess has been identified as a powerful 
predictor of premature atherosclerotic vascular disease in several large, 
prospective studies. Lipoprotein Lp(a) levels modulate the risk of coronary 
heart disease in patients with hypercholesterolemia, and lipoprotein Lp(a) 
excess is  commonly detected in men and women with premature coronary  
atherosclerosis. Lipoprotein Lp(a) contributes to atherothrombotic risk by 
multiple mechanisms that include impaired fibrinolysis, increased 
cholesterol deposition in the arterial wall, and enhanced oxidation of low 
density lipoprotein cholesterol. Although low density lipoprotein cholesterol 
therapy to lower lipoprotein Lp(a) may be indicated for patients with 
premature coronary atherosclerosis, a strong family history of premature 
atherosclerosis, or refractory hypercholesterolemia. In consideration of the 
high prevalence of lipoprotein Lp(a) excess in patients with premature 
coronary heart disease and the intricate role of lipoprotein Lp(a) in 
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atherothrombosis, this review provides an evidence-based approach to the 
screening and treatment of patients with lipoprotein Lp(a) excess. 
Modification of apolipoprotein(a) lysine binding site reduces 
atherosclerosis:     
                          Apolipoprotein(a) contains a major lysine binding site in one 
of its kringle domains. Destruction of this site by mutagenesis greatly 
reduces the binding of apolipoprotein(a) to lysine and fibrin. Transgenic 
mice expressing this mutant form of apolipoprotein(a) as well as mice 
expressing wild-type apolipoprotein(a) have been created in an inbred mouse 
strain. The wild-type apolipoprotein(a) transgenic mice have a fivefold 
increase in the development of lipid lesions, as well as a large increase in the 
focal deposition of apolipoprotein(a) in the aorta, compared with the lysine 
binding site mutant strain and to nontransgenic littermates. The results 
demonstrate the key role of this lysine binding site in the pathogenic activity 
of apolipoprotein(a) in a murine model system.(82) 
A prospective study of the role of lipoprotein(a) in the pathogenesis of 
unstable angina: 
             This study provides the first evidence in man of a significant role for 
lipoprotein(a) in unstable angina. The correlation between lipoprotein(a) 
concentration and cardiac Troponin T concentration suggests that 
lipoprotein(a) may be significantly involved in the early failure of plaque 
rupture stabilization.(83) 
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Contribution of Lp(a) to the occurrence of vascular diseases: 
                                      Lp(a) levels in patients with these vascular diseases 
were especially higher when there were known atherosclerotic risk factors 
such as diabetes mellitus, hypercholesterolemia or hypertension, although 
Lp(a) levels in patients with these risk-positive group was not different from 
that of control. These results suggest that Lp(a) contributes to the 
development of atherosclerotic vascular diseases especially when known 
atherosclerotic risk factors are not present. We also investigated the case of 
thromboangiitis obliterans, which is believed to develop from 
nonatherosclerotic mechanisms, and found that Lp(a) levels were higher  in 
such patients.(84) 
Lipoprotein (a) in the regulation of fibrinolysis: 
                                 Elevated plasma levels of lipoprotein(a) [LP(a)] are 
associated with increased  risk of developing atherosclerosis. This increased 
risk may be due to an Lp(a)-mediated depression of fibrinolytic activity. 
Lp(a) regulates fibrinolysis by controlling the activity of plasminogen 
activators. Lp(a) is a low density lipoprotein with an apoprotein(a) subunit 
which has a high degree of homology with the fibrinolytic zymogen 
plasminogen. The apoprotein(a) subunit contains up to thirty seven copies of 
a domain homologous to the plasminogen kringle 4 domain, which enables 
Lp(a) to bind to fibrin. The subunit also has a zymogen domain, but it is not 
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activated by plasminogen activators. Lp(a) inhibits plasminogen activation 
by competing with plasminogen for access to plasminogen activators bound 
to vascular surfaces. Lp(a) also competes with the irreversible inhibitor of 
plasminogen activators, plasminogen activator inhibitor-1. Therefore 
increases in Lp(a) concentration may decrease fibrinolytic activity by 
preventing activation of plasminogen, but Lp(a) may also prolong 
plasminogen activation by preventing the irreversible inhibition of the 
activators. At elevated levels of Lp(a) the decreased rate of plasmin 
generation may not be offset by the prolongation in plasminogen activation, 
and fibrinolysis will be inhibited. 
Homocysteine and lipoprotein(a) interact to increase CAD risk in young 
men and  women . 
                              Both elevated Homocysteine  and elevated Lp(a) showed 
evidence of being independent risk factors for CAD in men. The presence of 
both risk factors in men did not appear to confer additional risk. Consistent 
with prior studies, tHcy and Lp(a) are risk factors, either independently or in 
concert, for CAD in this clinical population. More significantly, we found 
evidence that when both risk factors were present in women, the associated 
risk was greater than what would be expected if the 2 risks were simply 
acting independently. The absence of such an interactive effect in men may 
be due to the confounding effects of age manifested as "survivor bias." These 
  
 
39 
clinical findings provide insights into the potential roles of both tHcy and 
Lp(a) in the pathogenesis of atherosclerosis. 
Social alcohol consumption and low Lp(a) lipoprotein concentrations : 
Light or moderate alcohol consumption decreases the risk of coronary heart 
disease. Beneficial changes in high density lipoprotein cholesterol 
concentrations are, however, observed at quite high levels of alcohol 
consumption—that is, 20 units per week, 1 unit being 10-12 g. Therefore, 
other factors may be responsible for decreasing the risk of coronary heart 
disease when alcohol is consumed in social amounts. The relation between 
light and moderate alcohol intake and Lp(a) lipoprotein concentrations was 
studied. Lp(a) lipoprotein is an independent risk factor for coronary heart 
disease and is affected by alcohol misuse. Study concluded that low Lp(a) 
lipoprotein concentrations may be one factor explaining low mortality and 
retarded progression of coronary artery disease in social drinkers. (85) 
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MATERIAL AND METHODS 
Selection of patients: 
                        Coronary heart disease patients of males <55 years and 
females < 65years (N=100) who were admitted to Coimbatore medical 
college hospital from January 2006 to June 2007  were recruited for the 
study based on clinical and electrocardiographic evidence suggestive of 
coronary artery disease.  
                         An informed consent was taken from all the patients. Patients 
with chronic liver and kidney disease and acute or chronic infections were 
not included in the study.  
Selection of controls: 
                                   Population based controls (N=50), normal 
symptomatically and electrocardiographically, without the presence of risk 
factors like smoking , alcohol, diabetes, hypertension, obesity and positive 
family history were included for this study. 
METHODS: 
The participants  of this study undergo Detailed history with special 
reference to 
1. Age, Sex. 
2. Smoking and alcohol habits, 
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3. Positive family history, 
4. History of diabetes,  
5. History of hypertension, 
6. History of hyperlipidemia, 
7. Detailed Physical examination, 
8. Anthropometric measurements – includes 
o Waist- hip ratio 
o Waist circumference 
o  Body mass index 
 
 
                             Fasting blood samples were drawn from all the 
participants of the study. Total cholesterol, triglycerides and high density 
lipoprotein cholesterol were estimated  using commercial kits on Beckman 
Cx4 autoanalyzer. Low-density lipoprotein (LDL) was  calculated using 
Friedewald’s formula .  
 
LDL cholesterol (mg/dl) = Total cholesterol – HDL cholesterol – 
(triglyceride/5) 
                         Total cholesterol/HDL-C ratio and LDL-C/HDL-C ratio were 
calculated. 
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                         Serum Lp(a) estimation was performed using quantitative  
Latex enhanced  immuno-turbidimetric method using Human Lp(a) kit. 
  
Desirable: < 14 mg/dL 
Borderline risk: 14 - 30 mg/dL 
High risk: 31 - 50 mg/dL 
Very high risk: > 50 mg/dL 
 
    Waist circumference more than 95cms for males and 85cms for 
females  BMI > 30, waist hip ratio >0.9 for females and >1.0 for male  were 
taken as obese and high risk for coronary artery disease 
 
                   High total cholesterol ( > 240mg/dl) , High Triglycerides 
 ( > 150mg/dl), High LDL (> 130mg/dl) and Low HDL (< 35mg/dl ) were 
considered as positive high risk factors for coronary artery disease. 
                           Serum Lipoprotein(a) value of more than 30mg/dl was 
taken as high risk factor for coronary artery disease. The mean values of 
LP(a) and the Lipid profile parameters were calculated among the cases and 
the controls and were compared. The frequencies of the distribution of each 
risk factor among the 100 cases were tabulated. The mean LP(a) values in 
those patients with each of the risk factor  and those patients without the risk 
factors were calculated separately and compared.  
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Fig-10 :Picture of a lipid profile auto analyzer 
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                                  OBSERVATIONS 
 
The results and observations of the study are presented below. 
 
CLINICAL PRESENTATION: 
 
In this study of 100 cases, 95 cases presented with typical anginal 
chest pain in the retrosternal region which lasted for about 15 min to several 
hours. Remaining cases presented with atypical symptoms. 32 of them had 
exertional dyspnea also along with chest pain. In 89 cases, examination of 
cardiovascular system showed no abnormalities. 9 cases had a loud A2  
sound and and ejection systolic murmur in the aortic area probably related to 
the Atheroslerosis.Two remaining Cases had a pan systolic murmur in the 
mitral area on auscultation suggestive of papillary muscle dysfunction. 
Respiratory system examination in 14 cases revealed bi basal crepitations 
indicative of cardiac failure. 
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RISK FACTORS ANALYSIS IN 100 CASES OF 
PREMATURE CORONARY ARTERY DISEASE: 
1.AGE  DISTRIBUTION: (table-2) 
 
AGE IN YEARS 
 
NO. OF PATIENTS/  
PERCENTAGE 
25 AND BELOW 1 
26-30 3 
31-35 5 
36-40 13 
41-45 16 
46-50 24 
51-55 33 
56-60 3 
61-65 2 
 
0
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                       Male patients of >55 years and female patients of >65 years 
were excluded from the study .The increased incidence of coronary artery 
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disease in the age group 51 – 55 years   is probably related to the age related 
progression of atherosclerosis.  
  
SEX DISTRIBUTION: 
The sex distributions of the 100 cases were tabulated below. 
Table-3:                                      
SEX  NO. OF PATIENTS/  
PERCENTAGE  
MALES 85 
FEMALES 15 
 
 
 NO. OF 
P AT IE NT S /  
P E RCE NT AGE  , 
85
 NO. OF 
P AT IE NT S /  
P E RCE NT AGE  , 
15
 NO. OF PATIENTS/ 
PERCENTAGE 
MALES
FEMALES
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OTHER RISK FACTORS: 
The distributions of other risk factors among the 100 premature CAD cases 
were as follows. 
(Table-4) 
 
RISK FACTORS No.OF PATIENTS/  
PERCENTAGE 
SMOKING 36 
ALCOHOL 35 
DIABETES 46 
HYPERTENSION 49 
OBESITY 39 
FAMILY HISTORY 33 
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LIPID PROFILE: 
The distribution of abnormal lipid profile values among the 100 cases were 
shown below. 
(Table-5) 
 
 
     RISK FACTORS
  
No. of PATIENTS/ 
PERCENTAGE
 
LDL >130 mg/dl 36 
HDL< 35 mg/dl 53 
TOTAL CHOLESTEROL>240 
mg/dl 
11 
TRIGLYCERIDES>150 mg/dl 32 
 TOTAL CHOLESTEROL/HDL 
RATIO>4.5 
61 
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LIPOPROTEIN (a): 
 
The mean Lipoprotein (a) among 100 patients of premature coronary 
heart disease was found to be 30.98mg/dl. Among the 100 patients, 46 of 
them have significantly raised serum LP(a) levels. 
 
(Table-6) 
SERUM LP(a) mg/dl No. of PATIENTS/ 
PERCENTAGE
 
Less than 30mg/dl 54 
 More than or equal to 30mg/dl 46 
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50 
 
 
 
SERUM LP(a) CONCENTRATION IN DIFFERENT AGE GROUPS: 
                  The mean serum 
 Lipoprotein (a) values in different age groups 
of  premature CHD patients are as follows. 
Table-7: 
 
 
 
 
 
                  
  
 
 
35 35.56
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SL.NO AGE IN YEARS MEAN LP
 
(a)mg/dl 
1. <25 35 
2. 26-35 35.56 
3. 36-45 22.63 
6. 46-55 32.65 
8. 56-65 32.42 
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SEX DISTRIBUTION: 
 
 
The mean serum
 Lipoprotein (a) values among the male and female 
Premature CHD patients is as follows. Higher
 Lipoprotein (a) levels were 
observed in female sex 
 
Table-8: 
 
SL.NO  SEX  MEAN 
LP(a)mg/dl 
1. males 28.42 
2. females 40.3 
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LP(a) AND SMOKING: 
 
                                         
                                    The mean serum Lipoprotein (a) level was calculated 
among the smokers and non smokers. Found to be higher in smokers 
than among non – smokers which is statistically significant. 
Table-9: 
 
SL.
NO 
RISK FACTOR NO.OF 
PATIENTS 
MEAN LP(a) 
mg/dl 
1. Smokers 36 32.30 
2. Non- smokers 64 29.04 
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LP(a) AND  ALCOHOL: 
                                   
                        Analsysis among alcoholics shows that there is no significant 
correlation between alcohol and serum
 Lipoprotein (a) levels. 
Alcoholics have low mean LP(a) levels than Non-alcoholics.  
Table-10: 
 
SL.
NO 
RISK FACTORS No.OF 
PATIENTS 
MEAN LP(a) 
mg/dl 
1. Alcoholics 35 27.8 
2. Non- Alcoholics 65 32.8 
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LP(a) AND DIABETES MELLITUS: 
                                      The mean LP(a) among the diabetic patients with 
CAD was found to be higher than the non-diabetics. 
Table-11: 
 
SL.
NO 
RISK FACTORS No.OF 
PATIENTS 
MEAN LP(a) 
mg/dl 
1. Diabetics 46 33.50 
2. Non- Diabetics 54 27.31 
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LP(a) AND HYPERTENSION: 
                         No significant difference in mean LP(a) levels were observed 
between hypertensives  and Normotensives. 
 
                      
Table-12: 
 
RISK FACTORS No.OF PATIENTS MEAN LP(a) 
mg/dl 
Hypertensives 49 30.2 
Normotensive 51 29.7 
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LP(a) AND  OBESITY: 
                The mean LP(a) among the Obese patients with CAD was found to 
be slightly higher than the Non-obese . 
 
Table-13: 
 
SL.
NO 
RISK FACTORS No.OF 
PATIENTS 
MEAN LP(a) 
mg/dl 
1. Obese BMI>30 39 31.8 
2. Non- Obese BMI<30 61 29.17 
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LP(a) AND  FAMILY HISTORY OF CAD: 
 
                                The mean LP(a) level among the patients with positive 
family history was 37.0 mg/dl which was significantly higher and about 60% 
of them had LP(a) level >30mg/dl . This showed that there is positive 
correlation between LP(a) level and patients with  positive family history. 
 
Table-14: 
 
RISK FACTORS No.OF 
PATIENTS 
MEAN LP(a) 
mg/dl 
Positive Family history 33 37.0 
No Family history 67 26.8 
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ANALYSIS  OF SERUM LP(a) LEVELS  WITH THE SERUM 
LIPID PROFILE: 
     
                   The mean Serum Lp(a) levels in the patients with normal and 
abnormal lipid profile values were calculated and tabulated below. 
 
Table-15: 
 
 
SL.NO RISK FACTORS MEAN LP(a) mg/dl 
1. Hypercholesterolemia 43.1 
 Normocholesterolemia 28.62 
2. LDL >130mg/dl 43.9 
 LDL <130mg/dl 22.51 
3. HDL < 35mg/dl 36.81 
 HDL > 35mg/dl 22.8 
4. Triglycerides>150mg/dl 38 
 Triglycerides<150mg/dl 26.8 
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SERUM LP(a) LEVELS WITH THE SERUM LIPID PROFILE 
 
 
 
 
 
                        In patients with premature CHD higher mean Lp(a) levels 
were observed in patients with hypercholesterolemia, high LDL levels, low 
HDL levels and hypertriglyceridemia than those with normal lipid profile. 
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COMPARISION BETWEEN CASES AND CONTROLS:
  
 
                      The results obtained from comparing the fasting lipid 
profile and fasting lipoprotein(a) values in 100 premature CAD cases and 50 
controls were as follows.  
     
TABLE-16: 
 
 
SL.NO DETAILS 
 
CHD Patients 
N=100 
MEAN VALUES 
CONTROLS 
N=50 
MEAN VALUES 
1.  Age (years) 
 
47.6 42.22 
2.  Sex(M/F) 
 
85/15 39/11 
3.  Total-C(mg/dl) 
 
176.5 167.1 
4.  HDL-C (mg/dl) 
 
35.9 43.5 
5.  Triglycerides (mg/dl) 
 
134.7 121.8 
6.  LDL-C (mg/dl) 
 
114 108.3 
7.  Total cholesterol/ 
HDL-C ratio 
5.2 4.2 
8.  LDL-C/HDL-C ratio 
 
3.9 2.6 
9.  Lp(a) (mg/dl) 
 
30.98 23.58 
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Significant difference in mean Lp(a) level was observed between 
patients and  Controls. The mean LP(a) values among the premature CAD 
patients were found to be higher than in controls.(30.98 vs23.58) 
                           The mean values of Triglycerides ,LDL, Total cholesterol,  
LDL-C, Total-C/HDL-C ratio and LDL-C/HDL-C ratio were found to be 
higher in patients when compared to controls. Higher percentage of low 
HDL-C (<35mg/dl) was observed in patients than in controls. 
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Fig-11   : ECG of a patient showing LBBB  with AWMI 
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Fig-12:ECG of a patient showiing Anterior wall  ischemia 
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Fig-13:CHEST X-RAY PA VIEW showing cardiomegaly – LVH 
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DISCUSSION 
 
              Higher mean Lp(a) levels were observed in patients than 
controls and difference was statistically significant. (30.9vs23.6). This is in 
agreement with earlier studies conducted in India and abroad  (89-
103).Higher mean levels of Lp(a) were observed in cases than control in 
studies reported in India which ranged from 12 to 49mg/dl in patients and 8 
to 24 mg/dl in healthy controls (91-97). Mean Lp(a) levels in patients and 
controls in our study were within the range of values reported in earlier 
Indian studies.  
                           Low levels of HDL-C observed in patients when compared 
to controls (43.5vs35.9) in the present study is in agreement with the other 
Indian Study(86). With respect to low levels of HDL-C our study is similar 
to other studies (86-88). 
                           Increased total-C(134.7vs121.8) and LDL-C(114vs108.3) 
levels are reported in patients than in controls (88-90). In our study similar 
findings were observed in patients against controls.  
                             Increased LDL-C/HDL-C ratio(3.9vs2.6) and total 
cholesterol /HDL ratio( 5.2vs4.2)were reported in patients when compared to 
controls (87,89). Similar observations were drawn in the present study. 
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  IN PREMATURE CAD PATIENTS, 
                                     This study showed higher Lp(a) levels in females 
when compared to males (40.3vs28.2) in patients and is in agreement with 
other reports (101,104,105). Pedreno et al. (99) showed no gender 
differences in Lp(a) levels in both patients and controls. Though influence of 
sex on Lp(a) is not established in literature and the higher levels of Lp(a) in 
females than in males may be due to lowering effect of testosterone in males 
(106) and presence of menopausal status (107) in women with Coronary 
Artery Disease or may be due to discrepancy in sample size. Further studies 
are needed to confirm this observation. 
   The mean Lp(a) levels in different age  groups of the 
patients varies between 22mg and 35mg . No specific age group shows 
higher LP(a) levels.  
   Smokers were found to have slightly higher mean LP(a) 
levels than Non-Smokers in this study (32.3vs29.04). Studies have shown 
that Elevated blood levels of Lp(a) and cigarette smoking together greatly 
exacerbate the risk of coronary heart disease. One study suggests that 
cigarette smoking specifically alters Lp(a) concentrations in the blood.   
                                           The mean  Lp(a) levels in this study were low in 
Alcoholics than among the non-alcoholics (27.8vs32.8). Finnish Population 
based studies have shown that low Lp(a) lipoprotein concentrations may be 
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one factor explaining low mortality and retarded progression of coronary 
artery disease in social drinkers.(85) 
                                 In this study, mean Lp(a) levels were  higher in 
diabetics than among non-diabetics(33.5vs27.3).  Mohan et al. (7) reported 
in a  study that Lp(a) levels were higher in NIDDM patients with or without 
Coronary Artery Disease than controls.                  
                                   No significant difference in mean LP(a) levels were 
observed between hypertensives  and Normotensives(30.2vs29.7) in this 
study. Studies have shown only weak positive correlation of LP(a) with 
systolic blood pressure.                                  
                                       Higher Lp(a) levels were observed in individuals 
with a strong family history of Coronary Artery Disease than in those 
without such history(37vs27.6) which is in agreement with other report 
(108). The disturbance in lipoprotein metabolism is often familial. Studies 
have shown that LP(a) excess is one of the common lipoprotein 
abnormalities among the family members. 
                                           Lp(a) level is an important determinant of Coronary 
Artery Disease among patients with familial and non-familial 
hypercholesterolemia (109). In the present study also higher Lp(a) levels 
were observed in patients with hypercholesterolemia than 
normocholesterolemia (43.1vs28.62)  
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                                            Lp(a) levels in our study were high in patients 
with LDL-C >130 mg/dl than patients having LDL-C <130 mg/dl 
(43.9vs22.51). Other studies (99) reported positive significant association of 
Lp(a) with LDL-C. In the present study strong positive correlation of Lp(a) 
with LDL-C was observed. The pathogenicity of Lp(a) is increased with high 
LDL and vice-versa (110,111) 
                                       Our study confirmed positive correlation of Lp(a) with 
Coronary Artery Disease at >30mg/dl, a cut-off level in South Indian 
population for risk assessment similar to the earlier studies . 
                           Higher mean values of Lp(a) in the present study may 
explain higher prevalence of Coronary Artery Disease reported in South 
Indian population. Females, patients with positive family history of 
Coronary Artery Disease, Diabetics ,hypercholesterolemia and those with 
LDLC >130 mg/dl showed higher Lp(a) levels. These findings indicate that 
these category of patients are at high risk of developing Coronary Artery 
Disease in future as evidence shows that Lp(a) excess increases the risk of 
Coronary Artery Disease in future depending on the absence or presence of 
concomitant risk factors . 
                                                        This observation suggests that in addition 
to conventional lipid profile, estimation of Lipoprotein(a) can prove to be a 
valuable tool in risk assessment of population in general and management of 
disease in particular.  
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SUMMARY 
                    Significant difference in mean Lipoprotein(a) level was 
observed between the premature Coronary Artery Disease  patients and 
controls (30.98vs23.58) .  
  The mean values of serum Triglycerides, LDL, Total 
cholesterol,  LDL-C, Total-C/HDL-C ratio and LDL-C/HDL-C ratio were 
found to be higher in premature Coronary Artery Disease  patients when 
compared to controls. 
                  In patients with Premature Coronary Artery Disease, higher 
Lipoprotein(a) levels were observed in female sex, those with family history 
of Coronary Artery Disease, Smokers, and Diabetics than in male sex, those 
without family history of Coronary Artery Disease, non-smokers and   non-
diabetics. 
    There is no significant difference in mean Lipoprotein(a) levels   
between hypertensives  and Normotensives in premature Coronary Artery 
Disease patients. 
                   Higher Lipoprotein(a) levels were observed in all premature 
Coronary Artery Disease patients with hypercholesterolemia, high LDL 
levels, low HDL levels and hypertriglyceridemia than those patients with 
normal serum lipid profile. 
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                 No significant difference in Lipoprotein(a) levels was observed 
with respect to age in premature Coronary Artery Disease patients. 
                     Alcoholics had lower levels of serum Lipoprotein(a) compared 
to the Non-alcoholics with coronary artery disease. 
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CONCLUSION 
• High serum Lipoprotein (a) levels are associated with premature   
coronary artery disease. 
 
• There is a strong positive  correlation of High serum Lipoprotein 
(a) levels with High serum LDL levels and those with positive 
family history. 
 
• High serum Lipoprotein (a) levels are seen in patients with 
Smoking and Diabetes. 
 
• There is no correlation of High serum Lipoprotein (a) levels 
with respect to age and Hypertension. 
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PROFORMA 
 
 
 NAME:                                 
 
 AGE:                                         SEX: M/F  
 
 OCCUPATION: 
 
    I.P.NO:     
 
        DIAGNOSIS: 
 
 COMPLAINTS: 
 
            HISTORY OF PRESENT ILLNESS:  
 CHEST PAIN 
        PALPITATION 
            DYSPNOEA 
          SYNCOPE 
         PND 
                                                                 ORTHOPNOEA 
 
 PAST HISTORY:        DIABETES/ HYPERTENSION / CAD 
 
 PERSONAL HABITS:   SMOKING / ALCOHOL 
 
 FAMILY HISTORY OF CAD :   
 
 DIET: VEG/NONVEG/MIXED 
 
 TREATMENT HISTORY:  DRUG INTAKE 
 
 
 
 
 GENERAL EXAMINATION:  
 
 OBESITY                                 : 
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 DYSPNOEA   : 
 CYANOSIS   : 
 CLUBBING   : 
 PITTING PEDAL EDEMA : 
 XANTHALESMA  : 
 TENDON XANTHOMAS : 
 ARCUS SENILIS  : 
 PULSE    : 
 BLOOD PRESSURE  : 
 WAIST CIRCUMFERENCE : 
 
 
          HEIGHT:   WEIGHT:    
 
 BMI:  
 
         WAIST:HIP RATIO: 
    
           
         CARDIOVASCULAR SYSTEM: 
 
 APICAL IMPULSE  S1  S2  S3 
 
 PERICARDIAL RUB 
   
PERIPHERAL VASCULAR SYSTEM: 
 
 RESPIRATORY SYSYEM: 
 
ABDOMEN: 
 
CENTRAL NERVOUS SYSTEM: 
 
 INVESTIGATION: 
 
   URINE ROUTINE : 
   BLOOD SUGAR   :  
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   BLOOD UREA  :  
   SERUM CREATININE: 
 
FASTING LIPID PROFILE:- 
TOTAL CHOLESTEROL:  mg% 
TGL:  mg%  
HDL: mg% 
          LDL:             mg% 
 
SERUM FASTING LIPOPROTEIN(a) : 
 
ELECTROCARDIOGRAM: 
 
CHEST X-RAY PA VIEW: 
 
ECHOCARDIOGRAM: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     MASTER CHART
S.No Name IP No Age Sex Occpn Smo Alco DM SHT Fam BMI W.H.R LP(a) LDL HDL TGL
king hol H/O
1 Ramaswamy13608 48 M Coolie + + + + - 32 1.08 35 130 38 100
2 Karuppan 15740 55 M Coolie - - - - + 23 0.8 10 117 39 110
3 Shekar 15826 41 M Coolie - - + + + 31 1.1 40 142 32 180
4 Kannan 16195 50 M Coolie + + - - - 31 1.02 30 182 34 170
5 Palaniswamy16201 52 M Coolie + + - + - 30 1.04 33.8 135 33 148
6 Karuppusamy16235 53 M Coolie + - + - - 31 0.9 36 171 34 150
7 Selvaraj 16326 44 M Coolie - - - + + 28 0.9 21 136 35 145
8 Moorty 16538 52 M Coolie + - + + + 32 1.2 37 154 36 140
9 Rajan 16773 50 M Coolie - - - + - 27 1.1 8 86 40 120
10 Arumugam 17068 39 M Coolie - - + + - 30 1.1 35.1 188 40 160
11 Natarajan 17419 44 M Coolie + - - - - 26 0.8 37 157 50 170
12 Anandkumar17883 45 M Coolie + - + + + 31 0.99 34.3 132 33 155
13 Ganesan 18491 40 M Coolie - - + + - 29 0.8 7 102 46 110
14 Ranjith 18572 28 M Coolie + - - - - 27 0.8 38.3 141 32 158
15 Selvaraj 19067 55 M Coolie - - + + - 29 0.9 11 70 46 120
16 Velumani 19589 40 M Coolie - - - - - 24 0.8 41 130 32 138
17 James 20146 43 M Coolie - + + + - 33 1.11 9 119 40 125
18 Chandran 20786 50 M Coolie + - - - - 29 0.97 9 65.8 40 131
19 Duraiswamy21831 54 M Coolie - - + + + 31 1.05 22 97 36 135
20 Eswaran 23608 40 M Coolie - + - - - 23 0.76 21 118 30 158
21 Selvan 23710 45 M Coolie +  + + + 33 1.18 9 113 35 110
22 Vadivel 23909 45 M Coolie + + + + - 32 1.19 10 110 36 121
23 Paramasivam24547 47 M Coolie - - + + - 31 1.1 30 187 34 145
24 Senthil 24528 29 M Coolie + + + + + 30 1 10.4 68 34 120
25 Karuppan 2E+05 40 M Coolie + + - - - 28 0.8 9.3 81.4 38 118
26 Shanmugam28273 53 M Coolie - - - - - 22 0.7 10 87 35 110
27 Loganathan28584 49 M Coolie - + + + - 33 1.21 29 136 56 152
28 Raju 29390 50 M Coolie - - - + - 31 1.11 30 115 32 148
29 Nanjamal 30530 40 M Coolie + + - - + 24 0.8 30.6 134 35 159
30 Gopal 30775 50 M Coolie - - + + - 28 0.91 9 93.6 34 102
31 Subbamal 40634 65 F Coolie - - - - + 28 0.6 9 100 36 108
32 Krishnamal4E+05 60 F Coolie - - + + - 30 0.9 7 89 38.4 110
33 Mohanraj 41876 41 M Coolie + + + + + 23 0.8 36 184 36 130
34 Siva 52396 38 M Coolie + + - - - 33 1.2 10 107 33 125
35 Jayaprakash42674 43 M Coolie +  + + - 27 0.9 11 85.4 38 128
36 Dhramaraj 43656 54 M Coolie + - - - - 29 0.9 10 70 39 160
37 Palaniswamy44415 51 M Coolie + + + + - 25 0.7 29 131 36 128
38 Batsha 46494 55 M Coolie + + - - - 34 1.31 30 130 34 118
39 Nanjappan 24156 54 M Coolie + + - - + 21 0.7 10.4 90 34 102
40 Palaniswamy42962 40 M Coolie - + + + - 24 0.6 69.8 84.8 38.8 145
41 Kittan 53756 50 M Coolie - - - + - 29 0.92 70.5 149 36 142
42 Ramdoss 53382 50 M Coolie - - - - - 21 0.6 11.2 41.6 31 130
43 Kaliyammal55560 60 F Coolie + - - - - 29 0.9 126 128 50 128
44 Pattammal 54520 43 F Coolie - - + - + 30 0.9 9.5 84.6 30 120
45 Rajendran 56395 46 M Coolie - + - - + 22 0.6 16.8 31.6 41 170
46 Valliyammal52241 55 F Coolie + - - - - 28 0.8 126 143 48 141
47 Thangaraj 56378 47 M Coolie - + - - + 27 0.9 14.4 108 31
48 Ayyasamy 56451 40 M Coolie - - - - - 28 0.17 22.3 76 41
49 Noormuhammed53901 54 M Coolie - - - - - 29 0.81 11.2 135 42
50 Subbalakshmi59098 42 F Coolie + - - - + 25 0.9 39.9 89.8 42
51 Samakayappan44064 53 M Coolie - - + - + 34 0.91 131 192 30 190
52 Manasevan59148 55 M Coolie + + - - - 29 0.81 33 119 31 102
53 Rajan 55148 51 M Coolie - - + + + 28 0.7 96 132 22 157
54 Karuppusamy60585 55 M Coolie - - - - - 31 1.1 35.2 113 30 110
55 Hari krishnan60434 55 M Coolie + + + + + 34 1.31 104 130 34 160
56 ELSE 56001 55 F Coolie - - + + + 29 0.8 123 129 34 198
57 Manikandan60532 40 M Coolie - - - - - 30 1.1 22 128 33 145
58 Shekbajan 62239 55 M Coolie - - + - - 28 1 78 113 34 115
59 Vadivel 62198 55 M Coolie - - + - - 29 0.89 9 122 36 151
60 Palaniswamy62062 43 M Coolie + + + - + 29 0.81 30 114 34 102
61 Selvan 62055 45 M Coolie - + + - - 33 0.81 8 76.6 38 100
62 Ganesan 62480 31 M Coolie - - - + - 32 1.7 57 132 30 153
63 Ranganathan62306 35 M Coolie + + - - + 25 0.75 9 72.2 38 104
64 Jeganadan 62229 55 M Coolie - + - - - 26 0.6 7 78.8 39 101
65 Shaigabeevi62285 45 F Coolie - - - + + 29 0.88 22 84.2 30 154
66 Periyaswamy61772 55 M Coolie + + + + - 27 1.1 10 67.4 38 103
67 Karuppan 61806 45 M Coolie - + - - - 23 0.71 8 91 37 110
68 Thangavel 61865 55 M Coolie - - + + + 31 0.95 21 133 31 118
69 Karuppan 6E+05 50 M Coolie - - + + - 30 0.94 29 182 33 158
70 Khandaraj 61998 42 M Coolie - + + + - 33 1.38 14 73.6 40 107
71 Malikathiyan61692 53 M Coolie - - - + - 30 1.1 36 187 30 100
72 Umjalalma 61894 65 F Coolie - + - - + 21 0.8 11 77 39 110
73 Shankar 61762 55 M Coolie - + - - - 28 0.8 12 79 38 115
74 Balan 61764 50 M Coolie - - - + + 29 0.9 27 111 34 151
75 Pandiyan 61721 39 M Coolie + + - - - 27 0.85 10 91 40 150
76 Palaniswamy61535 35 M Coolie + - + + - 31 1.1 32.7 100 30 158
77 Kuppuraj 61587 50 M Coolie + + + + - 26 1.81 8 91.4 39 103
78 Ayyavu 61613 50 M Coolie - - - - + 27 0.7 36 100 31 159
79 Raju 61644 48 M Coolie + - + + - 34 1.2 34.8 112 34 158
80 Kaliyappan 61677 40 M Coolie - + - - - 30 1.2 10 72 38 100
81 Ummari 60891 50 F Coolie - - + + - 31 1.91 10 82.6 34 117
82 Raju 61493 50 M Coolie - - - - + 21 1.91 37 105 33 159
83 Subramaniam615 55 M Coolie - - + + - 25 0.9 10 131 34 151
84 Premkumari61514 47 F Coolie - - + + - 26 0.8 20 118 31 157
85 Palaniappan60788 55 M Coolie - - - - + 24 0.9 31 83 33 120
86 Thirumalaiswamy61184 50 M Coolie + - + - - 20 0.7 33.1 82.8 33 121
87 Muthu 61263 54 M Coolie - - + + - 23 0.71 11 81.4 37 158
88 Manikandan61270 33 M Coolie - + - - + 21 0.6 36 137 31 160
89 Rajan 61273 40 M Coolie + - + + - 25 0.85 35 147 34 145
90 Sarojini 60737 50 F Coolie - - - - - 27 0.79 10 72 38 100
91 Saayed Shali60851 52 M Coolie - + - + - 28 0.71 8 124 34 116
92 Saminathan60873 23 M Coolie + - - + + 21 0.7 35 125 31 118
93 Umusalma 60894 60 F Coolie - - - - + 27 0.9 36 116 30 120
94 Synbal 60986 48 M Coolie - + - + - 30 0.9 10 77 38 100
95 Ganesan 61049 35 M Coolie - - - - - 29 0.9 35.6 195 30 125
96 Ramaswamy61119 52 M Coolie - - - - - 27 0.8 37 169 31 148
97 Saraswathi 61124 55 F Coolie - - + + - 31 1.1 21 142 34 140
98 Saradhimani61623 55 F Coolie - - + - - 31 1.1 35.2 131 30 110
99 Shanmugam61985 30 M Coolie - - + - - 30 1.08 58 110 30 200
100 Gandhimani63256 48 M Cooli - - + + + 33 0.8 85.7 135 31 118
Total TC/HDLLDL/HDL ECG CXR ECHO
Chol
198 5.21 3.42 AWMI WNL LVF
178 4.56 3 LWI WNL WNL
210 6.5 4.43 AWI WNL N
250 7.35 5.35 IWI WNL N
198 6 4.093 AWMI cardiomegaly LVD
241 7.08 50.2 IWI N N
200 5.71 3.88 UA N N
208 5.77 4.2 IWMI N LVF
150 3.75 2.15 AWMI N N
260 6.5 4.7 NSIEMIN N
241 4.82 3.14 UA N N
196 5.93 4 AWMI N LVD
170 3.69 2.21 AWMI cardiomegaly LVD
245 7.6 4.4 UA N N
140 3.04 1.52 IWI N LVF
190 5.93 4.06 AWMI cardiomegaly LVF
146 3.65 2.97 LWI N N
138 3.45 1.7 UA N N
160 4.44 2.69 AWMI N N
180 6 3.93 ASMI cardiomegaly LVD
170 4.85 3.22 UA N N
175 4.86 3.02 UA N N
250 7.35 5.5 UA N N
130 3.4 1.74 AWI N N
140 4 2.33 IWI N N
145 2.58 1.55 IWI N N
198 6.1 4.27 ASMI N N
180 5.14 3.28 ASMI cardiomegaly LVD
200 5.88 3.94 IWMI N N
150 4.16 15.5 UA N N
161 4.2 2.56 NSIEMIN N
145 4.02 2.47 AWI N N
243 7.36 5.57 ASMI cardiomegaly LVD
170 4.47 2.81 IWI N N
150 3.84 2.18 IWI N N
138 3.83 1.94 IWI N N
190 5.58 3.85 AWMI N N
188 5.52 3.82 ASMI N N
150 3.84 2.29 UA N N
148 4.11 2.43 IWI N N
208 6.7 4.7 IWI N N
112 2.24 0.82 ASMI cardiomegaly LVD
200 6.66 4.7 IWMI N N
174 4.24 2.1 IWI N N
112 2.33 0.64 IWI N N
200 6.75 4.6 UA N N
175 4.2 2.53 NSIEMIN N
142 3.38 1.8 WIW N N
201 4.78 2.97 ASMI N N
160 3.8 2.14 ASMI N N
260 8.6 6.4 LWI N N
170 5.48 3.93 AWHI cardiomegaly LVD
189 8.45 6 AWHI cardiomegaly LVD
165 5.5 3.76 LWMI cardiomegaly LVD
196 5.76 3.84 UA N N
203 5.97 3.79 UA N N
190 5.75 3.87 LWI N N
170 5 3.32 ASMI N N
188 5.22 3.88 ASMI N N
168 4.94 3.32 LWI N N
135 3.97 2.02 LWI N N
193 6.43 4.4 IWI N N
131 3.44 1.89 ASMI cardiomegaly LVD
138 3.53 2.02 ASMI cardiomegaly LVD
145 4.83 2.8 IWI N N
126 3.31 1.76 LWI N N
140 3.78 2.45 ASMI N N
188 6.06 4.29 ASMI N N
247 7.48 5.51 ASMI N N
135 3.75 1.84 ASMI N N
249 8.3 6.23 LWI N N
138 3.5 1.97 AWI N N
140 3.68 2.07 IWI cardiomegaly LVD
175 5.14 3.23 LWI N N
161 4.02 2.27 ASMI N N
162 5.4 3.34 ASMI N N
141 3.61 2.32 IWHI N N
163 5.25 3.22 AWMI N N
178 5.23 3.29 UA N N
130 3.42 1.89 NSIEMIN N
140 4.11 2.44 NSIEMIN N
170 5.15 3.18 NSIEMIN N
165 4.85 2.94 AWMI N N
180 5.29 3.8 IWMI N N
140 4.24 2.51 IWMI N N
151 4.57 2.51 US N N
150 4.05 2.18 NSIEMIN N
200 6.45 4.41 LWI N N
210 6.17 4.32 IWMI N N
130 3.42 1.89 ASMI N N
181 5.32 3.64 IWI N N
180 5.8 4.03 UA cardiomegaly LVD
170 5.66 3.86 NSIEMIN N
135 3.55 2.02 UA N N
250 8.33 6.5 ASMI N N
231 7.45 5.45 ASMI N N
204 6 4.17 ASMI N N
180 6 4.36 UA cardiomegaly LVD
180 6 3.66 NSIEMIN N
190 6.12 4.35 LWI N N
S.NO NAME AGE SEX LDL HDL TG TOTAL CH VCDL TC/HDL LDL/HDL Lp(a)
1 karuppusamy 50 M 126 28 130 180 26 6.43 4.5 30
2 Raman 40 M 75mg 52 116 150 23.2 2.59 1.44 13
3 Kumar 45 M 75 50 115 148 23 2.96 1.5 12
4 Mallika 51 F 76.8 50 116 150 23.2 3 1.54 14
5 Rangammal 45 F 66 40 120 130 24 3.4 1.65 15
6 Arivinda 28 M 75.6 52 122 152 24.4 2.35 1.442 17
7 Palaniyammal 50 F 103.4 43 123 171 24.6 3.97 2.39 18
8 Kuppan 50 M 144.4 33 138 215 27.6 6.515 4.36 40
9 Karuppayan 53 M 136 38 140 202 28 5.32 3.57 38
10 Gandhi 38 F 93.2 50 125 179 35.8 3.58 1.86 20
11 Palanisamy 48 M 113.8 41 126 180 25.2 4.39 2.78 17
12 Govindhan 40 M 94.4 42 118 160 23.6 3.8 2.23 18
13 Kuppathal 50 F 97 42 120 163 24 3.79 2.3 15
14 Rangamn 53 M 139.2 44 121 208 24.8 4.72 3.16 50
15 Masilamani 42 M 107.2 46 124 178 24.8 3.87 2.32 20
16 Kittan 50 M 105mg 40 125 170 25 4.25 2.625 19
17 Marriyammal 55 M 149.4 38 138 215 27.6 5.66 3.92 75
18 Gathi 28 F 117 59 120 175 24 3.39 1.98 39
19 Porravathy 38 F 127 37 130 200% 26 4.87 3.43 49
20 Joeshp 45 M 104.4 38 128 168% 25.6 4.42 2.73 57
21 Yooasaj 45 M 109.4 72 118 198 23.6 4.16 2.6 13
22 Manikkam 50 M 154.4 32 118 210 23.6 6.56 4.81 33
23 Nattayan 40 M 97 38 125 160 25 4.34 2.55 19
24 Lakshmi 50 F 91.4 48 128 165 25.6 3.43 1.917 14
25 Badaiyappan 45 M 102 48 100 170 20 3.54 2.125 17
26 Balan 40 M 102.8 52 116 178 23.2 3.42 1.96 18
27 Ramayappan 45 M 138.2 38 119 200 23.8 5.26 3.63 19
28 Selvaraj 30 M 117.4 37 118 178 23.6 4.8 3.16 14
29 Ayyasamy 20 M 94 44 110 160 22 3.6 2.13 13
30 Govindarajan 37 M 138 36 130 200 26 5.56 3.8 35
31 Kuppammal 50 F 132.4 44 118 200 23.6 4.54 3 36
32 Eswaran 40 M 130 36 140 194 28 5.38 3.61 17
33 Rangappan 48 M 127.4 35 138 190 27.6 5.42 3.62 18
34 Palaniyappan 43 M 118 36 129 180 25.8 5 3.27 17
35 Meena 25 F 95.8 39 126 160 25.2 4.1 2.46 19
36 Venkatachalam 36 M 95.4 46 118 165 23.6 3.59 2.06 14
37 Christopher 30 M 87.4 50 118 161 23.6 3.22 1.74 12
38 mantha 41 F 109 45 120 178 24 3.96 2.42 30
39 Ahakbar 38 M 102 39 123 165 24.6 4.8 2.615 13
40 Abraham 51 M 104.4 35 128 168 25.6 4.71 2.97 11
41 sivasamy 50 M 151.8 32 131 210 26.2 6.56 4.93 35
42 senthilkumar 30 M 119 58 116 200 23.2 3.45 2.05 39
43 Murugaran 43 M 79 47 118 150 23.6 3.19 1.68 17
44 Ramasamy 44 M 72 58 110 152 22 2.62 1.24 15
45 Ismayil 40 M 77.4 52 108 151 21.6 2.9 1.48 18
46 Manikandan 43 M 93 45 106 160 21.2 3.55 2.06 14
47 Narayanan 38 M 98.4 39 118 161 23.6 4.13 2.51 11
48 Mariyappan 49 M 156 28 120 208 24 7.14 5.57 38
49 Kuttiyappan 48 M 101 42 121 108 24.2 4 2.4 16
50 Karthikeyan 23 M 58.4 60 108 144 25.6 2.4 0.96 18
